EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Exact Sciences's Enterprise Value is $12,692 Mil.
Exact Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $32 Mil. Therefore, Exact Sciences's EV-to-FCF for today is 397.52.
The historical rank and industry rank for Exact Sciences's EV-to-FCF or its related term are showing as below:
EXAS'
s EV-to-FCF Range Over the Past 10 Years
Min: -656.21 Med: -24.18 Max: 536.83
Current: 397.52
During the past 13 years, the highest EV-to-FCF of Exact Sciences was 536.83. The lowest was -656.21. And the median was -24.18.
EXAS's EV-to-FCF is ranked worse than 93.14% of 102
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.58
vs EXAS: 397.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Exact Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's EV-to-FCF
For the Diagnostics & Research subindustry, Exact Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Exact Sciences's EV-to-FCF falls into.
Exact Sciences's current Enterprise Value is $12,692 Mil.
Exact Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Exact Sciences's PE Ratio for today is calculated as:
Exact Sciences's share price for today is $59.37.
Exact Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.136.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Exact Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Exact Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 